42783 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Sep 22
13:11 UTC
|
STZ
Constellation Brands
|
◎ Target | Lauren Lieberman ★★☆☆☆ #2347 | Equal Weight | $132.00→ $122.00-7.6% |
|
Sep 22
13:11 UTC
|
PSKY
Paramount Skydance
|
◎ Target | Benjamin Swinburne ★★★★★ #149 | Overweight | $10.00→ $11.50+15.0% |
|
Sep 22
13:11 UTC
|
OKTA
Okta
|
◎ Target | Shrenik Kothari ★★★☆☆ #1179 | Outperform | $185.00→ $200.00+8.1% |
|
Sep 22
13:11 UTC
|
NXT
Nextpower
|
◎ Target | Ben Kallo ★★★☆☆ #1161 | Outperform | $156.00→ $116.00-25.6% |
|
Sep 22
13:11 UTC
|
META
Meta Platforms
|
◎ Target | Brent Thill ★★★☆☆ #2071 | Buy | $710.00→ $875.00+23.2% |
|
Sep 22
13:11 UTC
|
LAD
Lithia Motors
|
◎ Target | Michael Ward ★★★☆☆ #2076 | Buy | $455.00→ $409.00-10.1% |
|
Sep 22
13:11 UTC
|
IONS
Ionis Pharmaceuticals
|
◎ Target | Jessica Fye ★★☆☆☆ #2368 | Overweight | $76.00→ $70.00-7.9% |
|
Sep 22
13:11 UTC
|
HTFL
Heartflow
|
◎ Target | William Plovanic ★★★☆☆ #2019 | Buy | $45.00→ $56.00+24.4% |
|
Sep 22
13:11 UTC
|
HNGE
Hinge Health
|
◎ Target | Vikram Kesavabhotla ★★★☆☆ #1052 | Neutral | $85.00→ $90.00+5.9% |
|
Sep 22
13:11 UTC
|
GRAL
GRAIL
|
◎ Target | Catherine Schulte not yet tracked | Outperform | $96.00→ $118.00+22.9% |
|
Sep 22
13:11 UTC
|
FICO
Fair Isaac
|
◎ Target | Jason Haas not yet tracked | Overweight | $1,450.00→ $1,350.00-6.9% |
|
Sep 22
13:11 UTC
|
EXC
Exelon
|
◎ Target | Marie Ferguson ★★★★☆ #442 | Buy | $52.00→ $49.00-5.8% |
|
Sep 22
13:11 UTC
|
EFX
Equifax
|
◎ Target | Jason Haas not yet tracked | Overweight | $212.00→ $200.00-5.7% |
|
Sep 22
13:11 UTC
|
DAR
Darling Ingredients
|
◎ Target | Manav Gupta ★★★★☆ #762 | Buy | $78.00→ $88.00+12.8% |
|
Sep 22
13:11 UTC
|
COLB
Columbia Banking System
|
◎ Target | Benjamin Gerlinger not yet tracked | Neutral | $32.00→ $31.00-3.1% |
|
Sep 22
13:11 UTC
|
ALKS
Alkermes
|
◎ Target | Joel Beatty ★☆☆☆☆ #2955 | Outperform | $58.00→ $61.00+5.2% |
|
Sep 22
13:11 UTC
|
ABVX
Abivax
|
◎ Target | David Nierengarten ★★★☆☆ #2231 | Neutral | $140.00→ $118.00-15.7% |
|
Sep 22
13:11 UTC
|
NFLX
Netflix
|
↓ Downgrade | firm only | Buy→ Hold | $76.00 |
|
Sep 22
13:11 UTC
|
DAVA
Endava
|
↓ Downgrade | Maggie Nolan ★★★☆☆ #1601 | Market Perform→ Underperform | |
|
Sep 22
13:11 UTC
|
WST
West Pharmaceutical Services
|
↑ Upgrade | Kallum Titchmarsh ★★★☆☆ #1731 | Equal Weight→ Overweight | $365.00→ $400.00+9.6% |
|
Sep 22
13:11 UTC
|
QNCX
Quince Therapeutics
|
↑ Upgrade | Jonathan Wolleben ★★★★★ #263 | Market Perform→ Outperform | $77.00 |
|
Sep 22
13:11 UTC
|
HFWA
Heritage Financial
|
↑ Upgrade | firm only | Neutral→ Buy | $33.00 |
|
Sep 22
13:11 UTC
|
FITB
Fifth Third Bancorp
|
↑ Upgrade | Benjamin Gerlinger not yet tracked | Neutral→ Buy | $59.00→ $62.00+5.1% |
|
Sep 22
13:11 UTC
|
AM
Antero Midstream
|
↑ Upgrade | firm only | Equal Weight→ Overweight | $25.00 |
|
Sep 22
12:11 UTC
|
XMTR
Xometry
|
◎ Target | Scott Devitt ★★★☆☆ #1820 | Buy | $110.00→ $120.00+9.1% |
|
Sep 22
12:11 UTC
|
WBD
Warner Bros. Discovery
|
◎ Target | Sean Diffley ★★☆☆☆ #2483 | Equal Weight | $29.00→ $31.00+6.9% |
|
Sep 22
12:11 UTC
|
TYRA
Tyra Biosciences
|
◎ Target | Mitchell S. Kapoor not yet tracked | Buy | $30.00→ $29.00-3.3% |
|
Sep 22
12:11 UTC
|
TWLO
Twilio
|
◎ Target | Catharine Trebnick ★★★☆☆ #2123 | Buy | $275.00→ $290.00+5.5% |
|
Sep 22
12:11 UTC
|
RXST
RxSight
|
◎ Target | Craig Bijou ★★☆☆☆ #2263 | Underperform | $6.50→ $5.50-15.4% |
|
Sep 22
12:11 UTC
|
PTCT
PTC Therapeutics
|
◎ Target | Kristen Kluska ★★★☆☆ #1676 | Overweight | $130.00→ $137.00+5.4% |
|
Sep 22
12:11 UTC
|
KYMR
Kymera Therapeutics
|
◎ Target | Alex Thompson not yet tracked | Buy | $132.00→ $152.00+15.2% |
|
Sep 22
12:11 UTC
|
ADPT
Adaptive Biotechnologies
|
◎ Target | Mark Massaro ★★★★☆ #614 | Buy | $25.00→ $34.00+36.0% |
|
Sep 22
12:11 UTC
|
ERIC
Ericsson
|
↓ Downgrade | Terrance Tsul not yet tracked | Equal Weight→ Underweight | $11.00→ $9.00-18.2% |
|
Sep 22
12:11 UTC
|
DAVA
Endava
|
↓ Downgrade | firm only | Market Perform→ Underperform | |
|
Sep 22
12:11 UTC
|
WST
West Pharmaceutical Services
|
↑ Upgrade | Kallum Titchmarsh ★★★☆☆ #1731 | Buy→ Overweight | $365.00→ $400.00+9.6% |
|
Sep 22
12:11 UTC
|
OMER
Omeros
|
↑ Upgrade | Olivia Brayer Saunders not yet tracked | Neutral→ Overweight | $22.00 |
|
Sep 22
12:11 UTC
|
MET
MetLife
|
↑ Upgrade | Paul Newsome ★★★☆☆ #1423 | Neutral→ Overweight | $99.00→ $110.00+11.1% |
|
Sep 22
12:11 UTC
|
EGO
Eldorado Gold
|
↑ Upgrade | Lawson Winder ★★★☆☆ #1562 | Underperform→ Buy | $32.00→ $54.00+68.8% |
|
Sep 22
12:11 UTC
|
EAT
Brinker International
|
↑ Upgrade | Jim Sanderson not yet tracked | Neutral→ Buy | $275.00 |
|
Sep 22
11:11 UTC
|
TBTG
The Beauty Tech Group
|
◎ Target | firm only | Buy | GBX 545→ GBX 600+10.1% |
|
Sep 22
11:11 UTC
|
SAA
M&C Saatchi
|
◎ Target | firm only | Buy | GBX 195→ GBX 175-10.3% |
|
Sep 22
11:11 UTC
|
HWG
Harworth Group
|
◎ Target | firm only | Buy | GBX 202→ GBX 195-3.5% |
|
Sep 22
11:11 UTC
|
BOOT
Henry Boot
|
◎ Target | firm only | Buy | GBX 219→ GBX 186-15.1% |
|
Sep 22
11:11 UTC
|
AXS
Accsys Technologies
|
◎ Target | firm only | Buy | GBX 130→ GBX 120-7.7% |
|
Sep 22
11:11 UTC
|
BRBY
Burberry Group
|
↓ Downgrade | firm only | Sec→ r perform | GBX 1,400→ GBX 1,200-14.3% |
|
Sep 22
11:11 UTC
|
MET
MetLife
|
↑ Upgrade | Paul Newsome ★★★☆☆ #1423 | Neutral→ Overweight | $110.00 |
|
Sep 22
11:11 UTC
|
FITB
Fifth Third Bancorp
|
↑ Upgrade | Benjamin Gerlinger not yet tracked | Neutral→ Buy | |
|
Sep 22
11:11 UTC
|
CWK
Cranswick
|
↑ Upgrade | firm only | Buy | GBX 5,770→ GBX 6,080+5.4% |
|
Sep 22
10:13 UTC
|
REPYY
Repsol
|
↓ Downgrade | firm only | Outperform→ Neutral | |
|
Sep 22
10:13 UTC
|
MET
MetLife
|
↑ Upgrade | Paul Newsome ★★★☆☆ #1423 | Neutral→ Overweight |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.